

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:**What is claimed is:**

1-48. **(Cancelled)**

49. **(Previously Presented)** A peptide consisting of the formula V, RX₆X₇X₈X₉ (SEQ ID No. 293),

wherein

X₆ is arginine, serine or lysine;

X₇ is leucine, isoleucine or valine;

X₈ is asparagine, alanine, glycine or isoleucine; and

X₉ is a natural or unnatural amino acid selected from the group consisting of leucine, cyclohexylalanine (Cha), homophenylalanine (Hof), tyrosine, parafluorophenylalanine (pFPhe), metafluorophenylalanine (mFPhe), tryptophan, 1-naphthylalanine (1Nal), 2-naphthylalanine (2Nal), metachlorophenylalanine (mClPhe), biphenylalanine (Bip) and 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Tic).

50. **(Currently Amended)** A peptide consisting of formula V,

RX₆X₇X₈X₉ (SEQ ID No. 293),

wherein:

X₆ is arginine, serine or lysine;

X₇ is leucine, isoleucine or valine;

X₈ is asparagine, alanine, glycine or isoleucine; and

X₉ is a natural or unnatural amino acid selected from the group consisting of leucine, cyclohexylalanine (Cha), homophenylalanine (Hof), tyrosine, parafluorophenylalanine (pFPhe), metafluorophenylalanine (mFPhe), tryptophan, 1-naphthylalanine (1Nal), 2-naphthylalanine (2Nal), metachlorophenylalanine (mClPhe), biphenylalanine (Bip) and 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Tic);

or a variant thereof wherein:

- (a) R is unchanged or conservatively substituted by a basic amino acid; and/or
- (b) X₆ is substituted by arginine, serine or lysine or any amino acid capable of providing at least one site for participating in hydrogen bonding; and/or
- (c) X₇ is unchanged-leucine, isoleucine or valine or conservatively substituted;
- (d) X₈ is asparagine, alanine, glycine or isoleucine or conservatively substituted; and
- (e) X₉ is a natural or unnatural amino acid selected from the group consisting of leucine, cyclohexylalanine (Cha), homophenylalanine (Hof), tyrosine, parafluorophenylalanine (pFPhe), metafluorophenylalanine (mFPhe), tryptophan, 1-naphthylalanine (1Nal), 2-naphthylalanine (2Nal), metachlorophenylalanine (mClPhe), biphenylalanine (Bip) and 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Tic).

51. **(Withdrawn - Currently Amended)** A peptide consisting of the formula V,

RX₆X₇X₈X₉ (SEQ ID No. 293),

wherein:

- X₆ is arginine, serine or lysine;
- X₇ is leucine, isoleucine or valine;
- X₈ is asparagine, alanine, glycine or isoleucine; and
- X₉ is a natural or unnatural amino acid selected from the group consisting of leucine, cyclohexylalanine (Cha), homophenylalanine (Hof), tyrosine, parafluorophenylalanine (pFPhe), metafluorophenylalanine (mFPhe), tryptophan, 1-naphthylalanine (1Nal), 2-naphthylalanine (2Nal), metachlorophenylalanine (mClPhe), biphenylalanine (Bip) and 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Tic);

or a variant thereof, wherein:

- (a) R is replaced by either a basic amino acid residue or an uncharged natural or unnatural amino acid residue; and/or
- (b) X₆ is arginine, serine or lysine or is replaced by a natural or unnatural amino acid residue, or an amino acid residue capable of forming a cyclic linkage; and/or
- (c) X₇ is leucine, isoleucine or valine or is replaced with a natural or unnatural amino acid residue having a slightly larger aromatic or aliphatic side chain; and/or
- (d) X₈ is asparagine, alanine, glycine or isoleucine or is replaced with a natural or unnatural amino acid residue having a slightly larger aromatic or aliphatic side chain; and

— (e) ~~X₉~~ is a natural or unnatural amino acid selected from the group consisting of leucine, cyclohexylalanine (Cha), homophenylalanine (Hof), tyrosine, parafluorophenylalanine (pFPhe), metafluorophenylalanine (mFPhe), tryptophan, 1-naphthylalanine (1Nal), 2-naphthylalanine (2Nal), metachlorophenylalanine (mClPhe), biphenylalanine (Bip) and 1,2,3,4-tetrahydroisoquinoline 3-carboxylic acid (Tic).

52. (Withdrawn) The peptide of claim 50, wherein R is conservatively substituted by a basic amino acid.

53. (Withdrawn) The peptide of claim 50, wherein X₆ is substituted by any amino acid capable of providing at least one site for participating in hydrogen bonding.

54. (Withdrawn) The peptide of claim 50, wherein X₇ is conservatively substituted.

55. (Cancelled)

56. (Cancelled)

57. (Withdrawn) The peptide of claim 51, wherein R is replaced by a basic residue.

58. (Withdrawn) The peptide of claim 57, wherein the basic amino acid residue is lysine.

59. (Withdrawn) The peptide of claim 51, wherein R is replaced by an uncharged natural or unnatural amino acid residue selected from the group consisting of citrulline (Cit), homoserine, histidine, norleucine (Nle) and glutamine.

60. (Withdrawn) The peptide of claim 51, wherein X₆ is replaced by a natural or unnatural amino acid residue, or an amino acid residue capable of forming a cyclic linkage.

61. (Withdrawn) The peptide of claim 60, wherein the natural or unnatural amino acid residue is selected from the group consisting of asparagine, proline, aminoisobutyric acid (Aib) and sarcosine (Sar).

62. **(Withdrawn)** The peptide of claim 60, wherein the amino acid residue capable of forming a cyclic linkage is ornithine.

63. **(Withdrawn)** The peptide of claim 51, wherein X₇ is replaced with a natural or unnatural amino acid residue having a slightly larger aromatic or aliphatic side chain.

64. **(Withdrawn)** The peptide of claim 63, wherein the natural or unnatural amino acid residue having a slightly larger aromatic or aliphatic side chain is selected from the group consisting of norleucine, norvaline, cyclohexylalanine (Cha), phenylalanine and 1-naphthylalanine (1Nal).

65. **(Withdrawn)** The peptide of claim 51, wherein X₈ is replaced with a natural or unnatural amino acid residue having a slightly larger aromatic or aliphatic side chain.

66. **(Withdrawn)** The peptide of claim 65, wherein the natural or unnatural amino acid residue having a slightly larger aromatic or aliphatic side chain is selected from the group consisting of norleucine, norvaline, cyclohexylalanine (Cha), phenylalanine and 1-naphthylalanine (1Nal).

67-68. **(Cancelled)**

69. **(Previously Presented)** The peptide as in any of claims 49-51, wherein the N-terminal is acylated.

70. **(Withdrawn)** The peptide of claim 50 or 51, wherein R is substituted by citrulline.

71. **(Currently Amended)** A peptide selected from the group consisting of:

H-	Arg	Arg	Leu	Asn	<u>PFFpFpPhe</u>	NH ₂	(SEQ ID No. 295)
H-	Arg	Arg	Leu	Asn	<u>MClFmClPhe</u>	NH ₂	(SEQ ID No. 296)
H-	Arg	Arg	Leu	Ala	<u>PFFpFpPhe</u>	NH ₂	(SEQ ID No. 298)
H-	Arg	Arg	Leu	Ala	<u>MClFmClPhe</u>	NH ₂	(SEQ ID No. 299)

H-	Arg	Arg	Leu	Gly	<u>PFFpFPhe</u>	NH ₂	(SEQ ID No. 301)
H-	Arg	Arg	Leu	Gly	<u>MClFmClPhe</u>	NH ₂	(SEQ ID No. 302)
H-	Arg	Arg	Ile	Asn	<u>PFFpFPhe</u>	NH ₂	(SEQ ID No. 304)
H-	Arg	Arg	Ile	Asn	<u>MClFmClPhe</u>	NH ₂	(SEQ ID No. 305)
H-	Arg	Arg	Ile	Ala	<u>PFFpFPhe</u>	NH ₂	(SEQ ID No. 307)
H-	Arg	Arg	Ile	Ala	<u>MClFmClPhe</u>	NH ₂	(SEQ ID No. 308)
H-	Arg	Arg	Ile	Gly	<u>PFFpFPhe</u>	NH ₂	(SEQ ID No. 310)
H-	Arg	Arg	Ile	Gly	<u>MClFmClPhe</u>	NH ₂	(SEQ ID No. 311)
H-	Arg	Arg	Val	Asn	<u>PFFpFPhe</u>	NH ₂	(SEQ ID No. 313)
H-	Arg	Arg	Val	Asn	<u>MClFmClPhe</u>	NH ₂	(SEQ ID No. 314)
H-	Arg	Arg	Val	Ala	<u>PFFpFPhe</u>	NH ₂	(SEQ ID No. 316)
H-	Arg	Arg	Val	Ala	<u>MClFmClPhe</u>	NH ₂	(SEQ ID No. 317)
H-	Arg	Arg	Val	Gly	<u>PFFpFPhe</u>	NH ₂	(SEQ ID No. 319)
H-	Arg	Arg	Val	Gly	<u>MClFmClPhe</u>	NH ₂	(SEQ ID No. 320)
H-	Arg	Ser	Leu	Asn	<u>PFFpFPhe</u>	NH ₂	(SEQ ID No. 322)
H-	Arg	Ser	Leu	Asn	<u>MClFmClPhe</u>	NH ₂	(SEQ ID No. 323)
H-	Arg	Ser	Leu	Ala	<u>PFFpFPhe</u>	NH ₂	(SEQ ID No. 325)
H-	Arg	Ser	Leu	Ala	<u>MClFmClPhe</u>	NH ₂	(SEQ ID No. 326)
H-	Arg	Ser	Leu	Gly	<u>PFFpFPhe</u>	NH ₂	(SEQ ID No. 328)
H-	Arg	Ser	Leu	Gly	<u>MClFmClPhe</u>	NH ₂	(SEQ ID No. 329)
H-	Arg	Ser	Ile	Asn	<u>PFFpFPhe</u>	NH ₂	(SEQ ID No. 331)
H-	Arg	Ser	Ile	Asn	<u>MClFmClPhe</u>	NH ₂	(SEQ ID No. 332)
H-	Arg	Ser	Ile	Ala	<u>PFFpFPhe</u>	NH ₂	(SEQ ID No. 334)
H-	Arg	Ser	Ile	Ala	<u>MClFmClPhe</u>	NH ₂	(SEQ ID No. 335)
H-	Arg	Ser	Ile	Gly	<u>PFFpFPhe</u>	NH ₂	(SEQ ID No. 337)
H-	Arg	Ser	Ile	Gly	<u>MClFmClPhe</u>	NH ₂	(SEQ ID No. 338)
H-	Arg	Ser	Val	Asn	<u>PFFpFPhe</u>	NH ₂	(SEQ ID No. 340)
H-	Arg	Ser	Val	Asn	<u>MClFmClPhe</u>	NH ₂	(SEQ ID No. 341)
H-	Arg	Ser	Val	Ala	<u>PFFpFPhe</u>	NH ₂	(SEQ ID No. 343)
H-	Arg	Ser	Val	Ala	<u>MClFmClPhe</u>	NH ₂	(SEQ ID No. 344)
H-	Arg	Ser	Val	Gly	<u>PFFpFPhe</u>	NH ₂	(SEQ ID No. 346)
H-	Arg	Ser	Val	Gly	<u>MClFmClPhe</u>	NH ₂	(SEQ ID No. 347)
H-	Arg	Lys	Leu	Asn	<u>PFFpFPhe</u>	NH ₂	(SEQ ID No. 349)
H-	Arg	Lys	Leu	Asn	<u>MClFmClPhe</u>	NH ₂	(SEQ ID No. 350)
H-	Arg	Lys	Leu	Ala	<u>PFFpFPhe</u>	NH ₂	(SEQ ID No. 352)
H-	Arg	Lys	Leu	Ala	<u>MClFmClPhe</u>	NH ₂	(SEQ ID No. 353)
H-	Arg	Lys	Leu	Gly	<u>PFFpFPhe</u>	NH ₂	(SEQ ID No. 355)
H-	Arg	Lys	Leu	Gly	<u>MClFmClPhe</u>	NH ₂	(SEQ ID No. 356)
H-	Arg	Lys	Ile	Asn	<u>PFFpFPhe</u>	NH ₂	(SEQ ID No. 358)
H-	Arg	Lys	Ile	Asn	<u>MClFmClPhe</u>	NH ₂	(SEQ ID No. 359)
H-	Arg	Lys	Ile	Ala	<u>PFFpFPhe</u>	NH ₂	(SEQ ID No. 361)
H-	Arg	Lys	Ile	Ala	<u>MClFmClPhe</u>	NH ₂	(SEQ ID No. 362)
H-	Arg	Lys	Ile	Gly	<u>PFFpFPhe</u>	NH ₂	(SEQ ID No. 364)
H-	Arg	Lys	Ile	Gly	<u>MClFmClPhe</u>	NH ₂	(SEQ ID No. 365)

H-	Arg	Lys	Val	Asn	<u>PFFpFPhe</u>	NH ₂	(SEQ ID No. 367)
H-	Arg	Lys	Val	Asn	<u>MClFmClPhe</u>	NH ₂	(SEQ ID No. 368)
H-	Arg	Lys	Val	Ala	<u>PFFpFPhe</u>	NH ₂	(SEQ ID No. 370)
H-	Arg	Lys	Val	Ala	<u>MClFmClPhe</u>	NH ₂	(SEQ ID No. 371)
H-	Arg	Lys	Val	Gly	<u>PFFpFPhe</u>	NH ₂	(SEQ ID No. 373)
H-	Arg	Lys	Val	Gly	<u>MClFmClPhe</u>	NH ₂	(SEQ ID No. 374)
H-	Arg	Arg	Leu	Ile	<u>PFFpFPhe</u>	NH ₂	(SEQ ID No. 375) <u>and</u>
H-	Cit	Cit	Leu	Ile	<u>PFFpFPhe</u>	NH ₂	(SEQ ID No. 376). <u>,</u>

72. **(Currently Amended)** The peptide of claim 71, wherein the peptide is selected from the group consisting of:

H-	Arg	Arg	Leu	Asn	<u>PFFpFPhe</u>	NH ₂	(SEQ ID No. 295)
H-	Arg	Arg	Leu	Asn	<u>MClFmClPhe</u>	NH ₂	(SEQ ID No. 296)
H-	Arg	Arg	Leu	Ala	<u>PFFpFPhe</u>	NH ₂	(SEQ ID No. 298)
H-	Arg	Arg	Leu	Ala	<u>MClFmClPhe</u>	NH ₂	(SEQ ID No. 299)
H-	Arg	Arg	Leu	Gly	<u>PFFpFPhe</u>	NH ₂	(SEQ ID No. 301)
H-	Arg	Arg	Leu	Gly	<u>MClFmClPhe</u>	NH ₂	(SEQ ID No. 302)
H-	Arg	Arg	Ile	Asn	<u>PFFpFPhe</u>	NH ₂	(SEQ ID No. 304)
H-	Arg	Arg	Ile	Asn	<u>MClFmClPhe</u>	NH ₂	(SEQ ID No. 305)
H-	Arg	Arg	Ile	Ala	<u>PFFpFPhe</u>	NH ₂	(SEQ ID No. 307)
H-	Arg	Arg	Ile	Ala	<u>MClFmClPhe</u>	NH ₂	(SEQ ID No. 308)
H-	Arg	Lys	Leu	Asn	<u>MClFmClPhe</u>	NH ₂	(SEQ ID No. 350)
H-	Arg	Lys	Leu	Ala	<u>PFFpFPhe</u>	NH ₂	(SEQ ID No. 352)
H-	Arg	Lys	Leu	Ala	<u>MClFmClPhe</u>	NH ₂	(SEQ ID No. 353)
H-	Arg	Lys	Leu	Gly	<u>PFFpFPhe</u>	NH ₂	(SEQ ID No. 355)
H-	Arg	Lys	Ile	Asn	<u>PFFpFPhe</u>	NH ₂	(SEQ ID No. 358) <u>and</u>
H-	Arg	Arg	Leu	Ile	<u>PFFpFPhe</u>	NH ₂	(SEQ ID No. 375). <u>,</u>

73. **(Currently Amended)** The peptide of claim 71, wherein the peptide is selected from the group consisting of:

H-	Arg	Arg	Leu	Asn	<u>PFFpFPhe</u>	NH ₂	(SEQ ID No. 295)
H-	Arg	Arg	Leu	Asn	<u>MClFmClPhe</u>	NH ₂	(SEQ ID No. 296)
H-	Arg	Arg	Leu	Ala	<u>PFFpFPhe</u>	NH ₂	(SEQ ID No. 298)
H-	Arg	Arg	Leu	Ala	<u>MClFmClPhe</u>	NH ₂	(SEQ ID No. 299)
H-	Arg	Arg	Leu	Gly	<u>PFFpFPhe</u>	NH ₂	(SEQ ID No. 301)
H-	Arg	Arg	Leu	Gly	<u>MClFmClPhe</u>	NH ₂	(SEQ ID No. 302)
H-	Arg	Arg	Ile	Asn	<u>PFFpFPhe</u>	NH ₂	(SEQ ID No. 304)
H-	Arg	Arg	Ile	Asn	<u>MClFmClPhe</u>	NH ₂	(SEQ ID No. 305)

H-	Arg	Arg	Ile	Ala	<u>PFFpFPhe</u>	NH ₂	(SEQ ID No. 307)
H-	Arg	Arg	Ile	Ala	<u>MClFmClPhe</u>	NH ₂	(SEQ ID No. 308)
H-	Arg	Lys	Leu	Asn	<u>MClFmClPhe</u>	NH ₂	(SEQ ID No. 350)
H-	Arg	Lys	Leu	Ala	<u>PFFpFPhe</u>	NH ₂	(SEQ ID No. 352)
H-	Arg	Lys	Leu	Ala	<u>MClFmClPhe</u>	NH ₂	(SEQ ID No. 353)
H-	Arg	Lys	Leu	Gly	<u>PFFpFPhe</u>	NH ₂	(SEQ ID No. 355)
H-	Arg	Lys	Ile	Asn	<u>PFFpFPhe</u>	NH ₂	(SEQ ID No. 358) <u>and</u>
H-	Arg	Arg	Leu	Ile	<u>PFFpFPhe</u>	NH ₂	(SEQ ID No. 375),